tiprankstipranks
Aquestive Therapeutics reports Q4 EPS (23c), consensus (23c)
The Fly

Aquestive Therapeutics reports Q4 EPS (23c), consensus (23c)

Reports Q4 revenue $10.68M, consensus $10.42M. "Our 2022 results and early progress in 2023 continue to drive the Company towards important upcoming inflection points," said Daniel Barber, CEO of Aquestive. "Our growing portfolio of approved products and collaborations around the world, along with our pipeline products, create the opportunity for significant long-term growth. Our lead pipeline asset, AQST-109, has the potential, if approved by the FDA and other regulatory bodies, to help the millions of patients who need to carry and depend on a rescue medication for allergic reactions. In addition, our continued progress towards the financial turnaround of the Company remains a key focus."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on AQST:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles